Cargando…

Tocilizumab cost effective in reducing COVID-19-related deaths

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8159658/
https://www.ncbi.nlm.nih.gov/pubmed/34075294
http://dx.doi.org/10.1007/s40274-021-7751-7
_version_ 1783700136254242816
collection PubMed
description
format Online
Article
Text
id pubmed-8159658
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-81596582021-05-28 Tocilizumab cost effective in reducing COVID-19-related deaths PharmacoEcon Outcomes News Clinical Study Springer International Publishing 2021-05-29 2021 /pmc/articles/PMC8159658/ /pubmed/34075294 http://dx.doi.org/10.1007/s40274-021-7751-7 Text en © Springer International Publishing AG 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Clinical Study
Tocilizumab cost effective in reducing COVID-19-related deaths
title Tocilizumab cost effective in reducing COVID-19-related deaths
title_full Tocilizumab cost effective in reducing COVID-19-related deaths
title_fullStr Tocilizumab cost effective in reducing COVID-19-related deaths
title_full_unstemmed Tocilizumab cost effective in reducing COVID-19-related deaths
title_short Tocilizumab cost effective in reducing COVID-19-related deaths
title_sort tocilizumab cost effective in reducing covid-19-related deaths
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8159658/
https://www.ncbi.nlm.nih.gov/pubmed/34075294
http://dx.doi.org/10.1007/s40274-021-7751-7